Response to Interferon-Free Direct Antivirals (DAAS) Treatment in HCV-Related Subcutaneous Lipoma-Like Marginal Zone B-Cell Lymphoma

Response to Interferon-Free Direct Antivirals (DAAS) Treatment in HCV-Related Subcutaneous Lipoma-Like Marginal Zone B-Cell Lymphoma

In 2010 a new entity termed “lipoma-like” HCV related marginal zone B-NHL was described. The etiological link between HCV infection and B-NHL has been extensively investigated in several epidemiological, biological and therapeutic studies and large experiences in literature demonstrated indolent l...

Full description

Bibliographic Details
Main Authors:	Maria Lucia De Luca, Laura Lombardi, Germana Tartaglia, Francesca Fazio, Alessio Di Prima, Laura Cesini, Alessandra Serrao, Martina Canichella, Alessandro Pulsoni
Format:	Article
Language:	English
Published:	PAGEPress Publications 2019-08-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	HCV, B-NHL, lipoma-like Marginal Zone Lymphoma, Direct-acting antiviral (DAAs)
Online Access:	http://mjhid.org/index.php/mjhid/article/view/3975

Similar Items

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
by: Chung-Feng Huang, et al.
Published: (2024-10-01)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
by: Reham M. Dawood, et al.
Published: (2022-08-01)

Elimination of HCV replication machinery early after antiviral treatment with DAA monitored by multimodal microscopy
by: Castro Victoria, et al.
Published: (2024-01-01)

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols
by: Valeria Caputo, et al.
Published: (2020-07-01)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
by: Ghias Un Nabi Tayyab, et al.
Published: (2020-04-01)

Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
by: Amr Maged Mahmoud Rasheed, et al.
Published: (2025-02-01)

Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients
by: Ghada M. Salum, et al.
Published: (2020-09-01)

HCV eradication in people living with HIV: the final countdown?
by: A. De Vito, et al.
Published: (2021-02-01)

Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection
by: Sara Romani, et al.
Published: (2019-06-01)

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
by: Mohammad Asrar Izhari
Published: (2023-09-01)

Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
by: Vincenzo Scaglione, et al.
Published: (2020-02-01)

Cardiac toxicity associated with HCV direct antiviral agents
by: Claudio Ucciferri, et al.
Published: (2018-10-01)

Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients
by: Mariantonietta Di Stefano, et al.
Published: (2021-09-01)

Recognition of 7 genes signature (Cirrhosis Risk Score) in the diagnosed non-responders to DAAs therapy by intra-PBMCs nested HCV RNA PCR
by: Al-Shazly Gaber Mohamed Galal, et al.
Published: (2023-08-01)

The Role of RASs /RVs in the Current Management of HCV
by: Konstantinos Malandris, et al.
Published: (2021-10-01)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
by: Devis Pascut, et al.
Published: (2020-06-01)

Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV
by: Zuzana Macek Jilkova, et al.
Published: (2021-12-01)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
by: Jian Zhang, et al.
Published: (2019-07-01)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
by: Vincenzo Messina, et al.
Published: (2020-12-01)

Intracranial lipoma associated with a subcutaneous lipoma
by: Toyin Oyemolade, et al.
Published: (2023-06-01)

The impact of HCV eradication using interferon-free direct acting antivirals on bone-mineral, anemia parameters and peripheral insulin resistance in hepatitis c-infected Egyptian hemodialysis cohort
by: Mahmoud M. Elnokeety, et al.
Published: (2023-10-01)

The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy
by: Nawfal R Hussein
Published: (2017-01-01)

Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
by: Irene Pericot-Valverde, et al.
Published: (2020-12-01)

The relation between SNPs in the NME1 gene and response to sofosbuvir in Egyptian patients with chronic HCV
by: Mohamed AbdElrahman, et al.
Published: (2023-01-01)

Long-Term Persistence of Mitochondrial DNA Instability among HCV-Cured People Who Inject Drugs
by: Mélusine Durand, et al.
Published: (2022-10-01)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
by: Stefania Farcomeni, et al.
Published: (2021-11-01)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
by: Pinchera B, et al.
Published: (2023-02-01)

The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia
by: Muhammad Begawan Bestari, et al.
Published: (2020-07-01)

Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection
by: Chih-Hsun Yi, et al.
Published: (2022-08-01)

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
by: Beatriz Álvarez, et al.
Published: (2020-06-01)

Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
by: Heng Lee, et al.
Published: (2021-10-01)

Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral–induced sustained virologic response
by: Sandra Franco, et al.
Published: (2023-01-01)

HCV Cascade of Care in HIV/HCV Co-Infected Individuals: Missed Opportunities for Micro-Elimination
by: Christos Thomadakis, et al.
Published: (2024-05-01)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
by: Claudia Minosse, et al.
Published: (2021-06-01)

Peripheral Neuropathy in Patients with Hepatitis C Infection—Reversibility after HCV Eradication: A Single Center Study
by: Theodoros Androutsakos, et al.
Published: (2024-03-01)

The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis
by: Serena Lorini, et al.
Published: (2020-11-01)

Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project
by: Vincenzo Messina, et al.
Published: (2022-05-01)

Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition
by: Giuseppina Maria Elena Colomba, et al.
Published: (2020-11-01)